目的 研究川崎病(KD)患儿血清25-羟基维生素D3[25-(OH)D3] 水平的变化及意义。方法 收集2012 年1 月至2015 年8 月242 例KD 患儿的临床资料,根据有无冠状动脉损伤(CAL)分为CAL组(63 例)和非CAL 组(NCAL,179 例),并且按照IVIG 治疗效果分为IVIG 敏感组(219 例)和IVIG 无反应组(23 例)。选择同期40 例健康儿童(对照组)和急性上呼吸道感染患儿40 例(上感组)为对照,通过酶联免疫法检测各组血清25-(OH)D3 水平。结果 IVIG 治疗前:上感组、NCAL 组和CAL 组25-(OH)D3 水平低于对照组(P<0.05),以CAL 组最低(P<0.05);上感组、IVIG 敏感组和IVIG 无反应组25-(OH)D3 水平均低于对照组(P<0.05),以IVIG 无反应组最低(P<0.05)。IVIG 治疗后:CAL 组的25-(OH)D3 水平低于NCAL 组及对照组(P<0.05);IVIG 无反应组的25-(OH)D3 水平低于IVIG 敏感组及对照组(P<0.05),以IVIG 无反应组最低(P<0.05)。结论 KD 患儿25-(OH)D3 水平下降,而且降低越明显,出现CAL 以及无反应型KD 的可能性越大。
Abstract
Objective To investigate the changes in the serum level of 25-hydroxyvitamin D3 [25-(OH)D3] and its significance in children with Kawasaki disease (KD). Methods The clinical data of 242 KD children were collected. According to the presence or absence of coronary artery lesion (CAL), these children were classified into CAL group (63 children) and non-CAL (NCAL) group (179 children). According to the efficacy of intravenous immunoglobulin (IVIG), these children were classified into IVIG-sensitive group (219 children) and no-IVIG-response group (23 children). A total of 40 healthy children (control group) and 40 children with acute upper respiratory tract infection (AURI group) were enrolled as controls. Enzyme-linked immunosorbent assay was applied to measure the serum level of 25-(OH)D3. Results Before IVIG treatment, the AURI, NCAL, and CAL groups had significantly lower serum levels of 25-(OH)D3 than the control group (P<0.05); the CAL group had a significantly lower serum level of 25-(OH)D3 than the AURI and NCAL groups (P<0.05); the AURI, IVIG-sensitive, and no-IVIG-response groups had significantly lower serum levels of 25-(OH)D3 than the control group (P<0.05); the no-IVIG-response group had a significantly lower serum level of 25-(OH)D3 than the AURI and IVIG-sensitive groups (P<0.05). After IVIG treatment, the CAL group had a significantly lower serum level of 25-(OH)D3 than the NCAL and control groups (P<0.05); the no-IVIG-response group had a significantly lower serum level of 25-(OH)D3 than the IVIG-sensitive and control groups (P<0.05). Conclusions KD children may experience a reduction in the serum level of 25-(OH)D3. With a greater reduction in the serum level of 25-(OH)D3, the possibility of CAL and KD with no response to treatment increases.
关键词
川崎病 /
25-羟基维生素D3 /
冠状动脉损伤 /
儿童
Key words
Kawasaki disease /
25-hydroxyvitamin D3 /
Coronary artery lesion /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Matsunaga A, Harita Y, Shibagaki Y, et al. Identification of 4-trimethylaminobutyraldehyde dehydrogenase (TMABADH) as a candidate serum autoantibody target for Kawasaki Disease[J]. PLoS One, 2015, 10(5): e0128189.
[2] Alhammadi AH, Hendaus MA. Comorbidity of Kawasaki disease and group A streptococcal pleural effusion in a healthy child: a case report[J]. Int J Gen Med, 2013, 6: 613-616.
[3] Bal AK, Prasad D, Pamintuan MAU, et al. Timing of intravenous immunoglobulin treatment and risk of coronary artery abnormalities in children with Kawasaki disease[J]. Pediatr Neonatol, 2014, 55(5): 387-392.
[4] Jeffery LE, Qureshi OS, Gardner D, et al.Vitamin D antagonises the suppressive effect of inflammatory cytokines on CTLA-4 expression and regulatory function[J]. PLoS One, 2015, 10(7): e0131539.
[5] Mozos I, Marginean O. Links between Vitamin D deficiency and cardiovascular diseases[J]. Biomed Res Int, 2015, 2015: 109275.
[6] Stagi S, Rigante D, Lepri G, et al. Severe vitamin D deficiency in patients with Kawasaki disease: a potential role in the risk to develop heart vascular abnormalities[J]. Clin Rheumatol, 2015: 1-8.
[7] Newburger JW, Takahashi M, Gerber MH, et al. Diagnosis, treatment, and long-term management of Kawasaki disease:a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association[J]. Pediatrics, 2004, 114(6): 1708-1733.
[8] 《中华儿科杂志》编辑委员会, 中华医学会儿科学分会心血 管学组, 中华医学会儿科学分会免疫学组. 川崎病专题讨论 会纪要[J]. 中华儿科杂志, 2007, 45(11): 826-830．
[9] 王新凤, 邓秀玲, 汪南平. 维生素D 在心血管疾病中的作用[J]. 生理科学进展, 2013, 44(3): 223-226.
[10] Vojinovic J, Cimaz R.Vitamin D-update for the pediatric rheumatologists[J]. Pediatr Rheumatol Online J, 2015, 13: 18.
[11] Nakamura Y. Epidemiology of Kawasaki disease[J].Nihon Rinsho, 2014, 72(9): 1536-1541.
[12] Liefaard MC, Ligthart S, Vitezova A, et al.Vitamin D and c-reactive protein: a mendelian randomization study[J]. PLoS One, 2015, 10(7): e0131740.
[13] Sommer A, Fabri M.Vitamin D regulates cytokine patterns secreted by dendritic cells to promote differentiation of IL-22-producing T Cells[J]. PLoS One, 2015, 10(6): e0130395.
[14] Hashemi SM, Mokhtari SM, Sadeqhi M, et al. Effect of vitamin D therapy on endothelial function in ischemic heart disease female patients with vitamin D deficiency or insufficiency: a primary report[J]. ARYA Atheroscler, 2015, 11(1): 54-59.
[15] 高卫卫, 李培, 施毅. 维生素D 对免疫系统的调节作用[J]. 中华哮喘杂志(电子版), 2013, 7(4): 43-46.
[16] Alyami A, Soares MJ, Sherriff JL, et al. A systematic review protocol examining the effect of vitamin D supplementation on endothelial function[J]. BMJ Open, 2015, 5(6): e006835.
[17] Kudo K, Hasegawa S, Suzuki Y, et al. 1α,25-Dihydroxyvitamin D(3) inhibits vascular cellular adhesion molecule-1 expression and interleukin-8 production in human coronary arterial endothelial cells[J]. J Steroid Biochem Mol Biol, 2012, 132(s 3-5): 290-294.
PDF(1083 KB)
